Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2018; 10(03): 289-293
DOI: 10.4103/JLP.JLP_176_17
Original Article

Clinical and laboratory standards institute versus European committee for antimicrobial susceptibility testing guidelines for interpretation of carbapenem antimicrobial susceptibility results for Escherichia coli in urinary tract infection (UTI)

Chinmoy Sahu
Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Vidhi Jain
Department of Microbiology, Yashoda Superspeciality Hospital, Kaushambi, Uttar Pradesh, India
,
Prabhakar Mishra
Department of Biostatistics and Health Informatics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
,
Kashi Nath Prasad
Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
› Author Affiliations Financial support and sponsorship Nil
› Further Information
Also available at
  PDF Download Permissions and Reprints

ABSTRACT

BACKGROUND: Carbapenems show excellent activity against resistant uropathogens, and they are the antibiotics of choice for urinary tract infections (UTIs). The choice of carbapenem prescription is strongly influenced by antimicrobial susceptibility testing (AST) report. With the publication of recent AST guidelines by the European Committee on AST (EUCAST), we were curious to evaluate the difference in results between Clinical and Laboratory Standards Institute (CLSI) and the EUCAST guidelines for the interpretation of carbapenems.

METHODS: During a period of 1 year, midstream urine specimens received in the laboratory were cultured by conventional techniques and 2932 of them grew significant colony counts of Escherichia coli. Out of them, 501 E. coli isolates which were resistant to at least six first-line antibiotics were further subjected to second-line antimicrobials imipenem and meropenem, reported by E-tests (bioMerieux, France). The E-test results were interpreted by both CLSI 2016 and EUCAST 6.0 (2016) guidelines. Weighted kappa was used to determine absolute agreement, and McNemar’s Chi-square test was used to test the difference in proportions of susceptibility between two methods, respectively.

RESULTS: Taking CLSI guidelines as a gold standard, there was 100% sensitivity in a susceptible category by the EUCAST guidelines for both the carbapenems. Weighted kappa showed good and moderate agreement between them for imipenem and meropenem, respectively. However, McNemar Chi-square test in the nonsusceptible category between the two tests was 9.38% and 33.03% for imipenem and meropenem, respectively, and they were highly significant (P < 0.001).

Conclusions: A laboratory can follow EUCAST guidelines as well and the guidelines are more useful in urinary concentrated antibiotics such as carbapenems. Further other antibiotics need to be evaluated by both these guidelines.

Keywords

Carbapenem - Clinical and Laboratory Standards Institute - European Committee on antimicrobial susceptibility testing - interpretation


Publication History

Received: 09 December 2017

Accepted: 04 April 2018

Article published online:
19 February 2020

© 2018.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 CLSI. Performance Standards for Antimicrobial Susceptibility Testing CLSI Supplement M100S. 26th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
  • 2 The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 6.0, 2016. Available from: http://www.eucast.org. [Last accessed on 2017 Nov 05].
  • 3 CLSI. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100. 27th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
  • 4 The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 7.0, 2017. Available from: http://www.eucast.org. [Last accessed on 2017 Nov 05].
  • 5 Süzük S, Kaşkatepe B, Avcıküçük H, Aksaray S, Başustaoǧlu A. [The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST]. Mikrobiyol Bul 2015;49:494-501.
  • 6 Mackie TJ, Collee JG, McCartney JE. Mackie & McCartney Practical Medical Microbiology. New York: Churchill Livingstone; 1996.
  • 7 Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, et al., (ed). Manual of Clinical Microbiology, 11th ed. ASM Press, Washington, DC. 2015.
  • 8 Hombach M, Böttger EC, Roos M. The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidelines. Clin Microbiol Infect 2013;19:E59-71.
  • 9 Wolfensberger A, Sax H, Weber R, Zbinden R, Kuster SP, Hombach M, et al. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: Influence on cumulative hospital antibiograms. PLoS One 2013;8:e79130.
  • 10 Kassim A, Omuse G, Premji Z, Revathi G. Comparison of clinical laboratory standards institute and European committee on antimicrobial susceptibility testing guidelines for the interpretation of antibiotic susceptibility at a university teaching hospital in Nairobi, Kenya: A cross-sectional study. Ann Clin Microbiol Antimicrob 2016;15:21.
  • 11 Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in gram-negative bacteria. Biomed Res Int 2014;2014:249856.